Lancet Oncol.

2018/01/01

Tanimoto T, Tsuda K, Oshima K, Mori J, Shimmura H.

Carfilzomib for relapsed or refractory multiple myeloma.

Lancet Oncol.19:e1, 2018.(Jan)

 

https://www.ncbi.nlm.nih.gov/pubmed/29304356

Share on Facebook
Share on Twitter
Please reload